AU2019237991B2 - JAK inhibitors - Google Patents

JAK inhibitors Download PDF

Info

Publication number
AU2019237991B2
AU2019237991B2 AU2019237991A AU2019237991A AU2019237991B2 AU 2019237991 B2 AU2019237991 B2 AU 2019237991B2 AU 2019237991 A AU2019237991 A AU 2019237991A AU 2019237991 A AU2019237991 A AU 2019237991A AU 2019237991 B2 AU2019237991 B2 AU 2019237991B2
Authority
AU
Australia
Prior art keywords
methyl
pyrrolo
pyrimidin
amino
azaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019237991A
Other languages
English (en)
Other versions
AU2019237991A1 (en
Inventor
Xibin Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2019237991A1 publication Critical patent/AU2019237991A1/en
Application granted granted Critical
Publication of AU2019237991B2 publication Critical patent/AU2019237991B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019237991A 2018-03-21 2019-03-18 JAK inhibitors Active AU2019237991B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646167P 2018-03-21 2018-03-21
US62/646,167 2018-03-21
PCT/US2019/022657 WO2019182924A1 (en) 2018-03-21 2019-03-18 Jak inhibitors

Publications (2)

Publication Number Publication Date
AU2019237991A1 AU2019237991A1 (en) 2020-10-15
AU2019237991B2 true AU2019237991B2 (en) 2025-01-02

Family

ID=67986579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019237991A Active AU2019237991B2 (en) 2018-03-21 2019-03-18 JAK inhibitors

Country Status (7)

Country Link
US (1) US11365188B2 (https=)
EP (1) EP3768272B1 (https=)
JP (1) JP7462951B2 (https=)
CN (1) CN111936144B (https=)
AU (1) AU2019237991B2 (https=)
CA (1) CA3093706A1 (https=)
WO (1) WO2019182924A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
KR20240026521A (ko) 2017-03-23 2024-02-28 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
JP2022506682A (ja) * 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ，インコーポレーテッド 化合物
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
WO2020155931A1 (zh) 2019-01-30 2020-08-06 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
WO2022117075A1 (zh) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140336207A1 (en) * 2011-12-21 2014-11-13 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof
US20170247373A1 (en) * 2014-02-28 2017-08-31 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368464B (es) 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
EP3180344B1 (en) * 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
EP3248980B1 (en) 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Jak inhibitor
WO2018169700A1 (en) 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140336207A1 (en) * 2011-12-21 2014-11-13 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof
US20170247373A1 (en) * 2014-02-28 2017-08-31 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof

Also Published As

Publication number Publication date
CA3093706A1 (en) 2019-09-26
CN111936144A (zh) 2020-11-13
WO2019182924A1 (en) 2019-09-26
EP3768272A4 (en) 2021-08-11
US20210053943A1 (en) 2021-02-25
EP3768272B1 (en) 2025-07-30
EP3768272A1 (en) 2021-01-27
JP7462951B2 (ja) 2024-04-08
JP2021518379A (ja) 2021-08-02
CN111936144B (zh) 2023-12-22
AU2019237991A1 (en) 2020-10-15
US11365188B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
AU2019237991B2 (en) JAK inhibitors
JP7793529B2 (ja) Ｋｃｃ２調節剤としての縮合ピリミジン化合物
KR101792837B1 (ko) 키나아제 억제제로서 사용을 위한 이미다조피라진
AU2018392616B2 (en) Quinazolinones as PARP14 inhibitors
US11974999B2 (en) Bruton's tyrosine kinase inhibitors
US20200109153A1 (en) Heteroaryl compounds that inhibit g12c mutant ras proteins
US12435079B2 (en) Bruton's tyrosine kinase inhibitors
CA2619365A1 (en) Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
CN110621675A (zh) 用于治疗增殖性疾病的三环化合物
TR201809140T4 (tr) Terapötik olarak aktif pirazolo-pirimidin türevleri.
CN116813647B (zh) 一类含氮稠环类sting调节剂类化合物、制备方法和用途
CN109721600B (zh) 一类含氮稠环化合物及其制备方法和用途
CA3130049C (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
CN102656172B (zh) 8-氧代二氢嘌呤衍生物
CN111763217B (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
US12234222B2 (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
JP2018529724A (ja) キナーゼ阻害剤としての縮合ピリジン誘導体
US9771351B2 (en) Wnt signaling inhibitor
CN113943251B (zh) 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途
CN119365455A (zh) 对溴结构域有活性的化合物
HK1232524B (zh) 新的咪唑并哒嗪类化合物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)